Skip to content
10-Q

Quarterly Report

Inhibitor Therapeutics, Inc. INTI

0001641172-25-010110

← back to feed
Filed
May 14, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · May 14, 2025 172.32M sh
Cash And Equivalents Q1 2025 · Mar 31, 2025 $4.32M
Cash And Equivalents Q1 2025 · Dec 31, 2024 $5.61M
Current Liabilities Q1 2025 · Mar 31, 2025 $94.71K
Current Liabilities Q1 2025 · Dec 31, 2024 $709.62K
Total Liabilities Q1 2025 · Mar 31, 2025 $3.15M
Total Liabilities Q1 2025 · Dec 31, 2024 $3.71M
Current Assets Q1 2025 · Mar 31, 2025 $4.42M
Current Assets Q1 2025 · Dec 31, 2024 $5.69M
Total Assets Q1 2025 · Mar 31, 2025 $4.51M
Total Assets Q1 2025 · Dec 31, 2024 $5.69M
Stock Issued Q1 2025 · Mar 31, 2024 270K sh
Shares Diluted Q1 2025 · Mar 31, 2024 172.08M sh
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$1.16M
Stockholders Equity Q1 2025 · Mar 31, 2024 $4.64M
Stockholders Equity Q1 2025 · Dec 31, 2023 $5.28M
Eps Diluted Q1 2025 · Mar 31, 2024 $0.00
Eps Basic Q1 2025 · Mar 31, 2024 $0.00
Sga Expense restated Q1 2025 · Mar 31, 2024 $514.46K
Rd Expense restated Q1 2025 · Mar 31, 2024 $260.36K
Net Income Q1 2025 · Mar 31, 2024 −$684.71K
Operating Income Q1 2025 · Mar 31, 2024 −$774.82K